Patent classifications
C07D245/02
Syringolin analogues and methods of making and using same
The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject.
Syringolin analogues and methods of making and using same
The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject.
MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS
The compounds of the present invention are represented by the following compounds having Formula I and Formula (I):
##STR00001##
where the substituents R.sup.1, R.sup.2, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R, R, X, Y, and Z are as defined herein and
##STR00002##
where the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R, R, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.
New Methods for 1,4-Diazo N-Heterocycle Synthesis
The present disclosure relates to novel synthetic method of making 1, 4-diazo N-heterocycles via intermolecular amphoteric diamination of allenes, and to the compounds made by the novel synthetic method.
New Methods for 1,4-Diazo N-Heterocycle Synthesis
The present disclosure relates to novel synthetic method of making 1, 4-diazo N-heterocycles via intermolecular amphoteric diamination of allenes, and to the compounds made by the novel synthetic method.
Novel Syringolin Analogues and Methods of Making and Using Same
The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject.
Novel Syringolin Analogues and Methods of Making and Using Same
The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject.
HIGH CHARGE DENSITY METALLOPHOSPHATE MOLECULAR SIEVES
A new family of highly charged crystalline microporous metallophosphate molecular sieves designated MeAPO-81 has been synthesized. These metallophosphates are represented by the empirical formula of:
R.sup.p+.sub.rA.sup.+.sub.mM.sup.2+E.sub.yPO.sub.z
where A is an alkali metal such as potassium, R is at least one quaternary ammonium cation of which one must be a cyclic diquaternary organoammonium cation such as N,N,N,N-tetramethyl-N,N-butano-1,6-hexanediammonium, M is a divalent metal such as zinc and E is a trivalent framework element such as aluminum or gallium. The MeAPO-81 family of materials has the BPH topology. The MeAPO-81 family of materials is among the first MeAPO-type molecular sieves to be stabilized by combinations of alkali and organoammonium cations, enabling unique high charge density compositions. The MeAPO-81 family of molecular sieves has catalytic properties for carrying out various hydrocarbon conversion processes and separation properties for separating at least one component.
HIGH CHARGE DENSITY METALLOPHOSPHATE MOLECULAR SIEVES
A new family of highly charged crystalline microporous metallophosphate molecular sieves designated MeAPO-81 has been synthesized. These metallophosphates are represented by the empirical formula of:
R.sup.p+.sub.rA.sup.+.sub.mM.sup.2+E.sub.yPO.sub.z
where A is an alkali metal such as potassium, R is at least one quaternary ammonium cation of which one must be a cyclic diquaternary organoammonium cation such as N,N,N,N-tetramethyl-N,N-butano-1,6-hexanediammonium, M is a divalent metal such as zinc and E is a trivalent framework element such as aluminum or gallium. The MeAPO-81 family of materials has the BPH topology. The MeAPO-81 family of materials is among the first MeAPO-type molecular sieves to be stabilized by combinations of alkali and organoammonium cations, enabling unique high charge density compositions. The MeAPO-81 family of molecular sieves has catalytic properties for carrying out various hydrocarbon conversion processes and separation properties for separating at least one component.
NOVEL COMPOUND FOR LIGHT EMITTING DEVICE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING SAME
A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:
##STR00001##